证券代码：688137 证券简称：近岸蛋白 公告编号：2025-027 苏州近岸蛋白质科技股份有限公司 关于持股 5%以下股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 股东上海乔贝投资管理合伙企业（有限合伙）－菏泽乔贝京煦创业投资合伙 企业（有限合伙）有限公司（以下简称"菏泽乔贝"）持有苏州近岸蛋白质科技 股份有限公司（以下简称"公司"）795,292 股股份，占公司总股本比例为 1.1333%； 股东上海普近科技发展合伙企业（有限合伙）（以下简称"上海普近"）持有公司 263,158 股股份，占公司总股本比例为 0.3750%。 减持计划的主要内容 1 | 股东名称 | 上海普近 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：5%以下股 ...

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-026 苏州近岸蛋白质科技股份有限公司 具 体 内 容 详 见 公 司 于 2024 年 9 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《苏州近岸蛋白质科技股份有限公司关于稳定股价措 施暨以集中竞价方式回购股份方案的公告》（公告编号：2024-041）。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 7 7 | 年 | 月 | 27 | 日~2025 | 年 | 月 | 26 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激 ...

Core Insights - Nearshore Protein (688137) is focusing on protein tool innovation and applications, providing timely and high-quality products and services for innovative drug development companies and other life health application enterprises [1][2] - The company reported a revenue of 128 million yuan for the fiscal year 2024, a year-on-year decrease of 16.73%, and a net profit attributable to the parent company of -54.4163 million yuan, a significant decline of 523.68% [1] Group 1 - The company has increased investments in product quality improvement and business expansion to adapt to market changes and achieve high-quality development [1] - Nearshore Protein has made substantial progress in expanding its overseas market presence, establishing international professional teams in key markets such as the United States and Europe [2] - The global sales network now covers multiple major countries and regions, with a focus on core customer groups including international pharmaceutical companies, biotech firms, and research institutions [2] Group 2 - The company is enhancing the application of AI in the life sciences sector while advancing the industrialization of various synthetic biology projects, including collagen raw materials [2] - Nearshore Protein is actively seeking collaboration investments and acquisitions related to its main business to integrate upstream and downstream industry chain resources, enriching its industrial layout and creating a new industry ecosystem [2]

Core Points - The company, Suzhou Novoprotein Technology Co., Ltd., will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 30, 2025, from 16:00 to 17:00 [1] - The briefing will be conducted online via the Value Online platform, allowing for interactive communication with investors [1][2] - Investors can submit questions prior to the meeting through a designated website or by scanning a QR code [1] Meeting Details - Meeting Date and Time: June 30, 2025, from 16:00 to 17:00 [1] - Meeting Location: Value Online (www.ir-online.cn) [1] - Meeting Format: Online interactive session [1] Participants - Key attendees will include the Chairman and General Manager, Mr. Zhu Huaxing, the Vice General Manager and Board Secretary, Mr. Wang Duqiang, and the Chief Financial Officer, Mr. Zhang Dongye [1] Investor Participation - Investors can join the meeting through the provided website or by scanning a QR code on the day of the event [1] - Questions can be submitted before the meeting for the company to address during the session [1] Contact Information - Contact Department: Securities Affairs Department [1] - Phone: 021-50798028 [1] - Email: IR@novoprotein.com.cn [1] Additional Information - After the meeting, investors can access the details and main content of the performance briefing on the Value Online platform or via the Yidong app [1]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-025 苏州近岸蛋白质科技股份有限公司 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了《2024 年年度报告》《2024 年年度报告摘要》及《2025 年第一季度报告》。为便于广大投资者更加全面深 入地了解公司经营业绩、发展战略等情况，公司定于 2025 年 06 月 30 日（星期 会议召开时间：2025 年 06 月 30 日（星期一）16:00-17:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 06 月 30 日 前 访 问 网 址 https://eseb.cn/1prL7NacKg8 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 一）16:00-17:00 在"价值在线"（www.ir-online.cn）举办苏州近岸蛋白质科 技股份有限公司 2024 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-023 苏州近岸蛋白质科技股份有限公司 关于开立募集资金现金管理产品专用结算账户的公告 根据《上市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监 管指引第1号——规范运作》等相关规定，上述账户将专用于暂时闲置募集资金进行 现金管理的结算，不会用于存放非募集资金或用作其他用途。公司将在产品到期且 无后续使用计划时及时注销以上专户。 二、风险控制措施 1、公司将严格按照《上市公司募集资金监管规则》《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》《上海证券交易所科创板股票上市规则》 等有关规定办理相关现金管理业务。 2、公司按照决策、执行、监督职能相分离的原则建立健全现金管理的审批和执 行程序，有效开展和规范运行现金管理的投资产品购买事宜，确保资金安全。 3、公司将严格遵守审慎投资原则筛选投资对象,主要选择信誉好、规模大、有 能力保障资金安全的发行主体所发行的产品。 4、公司财务部相关人员将及时分析和跟踪投资产品的投向、项目进展情况，如 评估发现存在可能影响公司资金安全的风险因素，将及时采取相应保全措施,控制理 财风险。 本 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-022 苏州近岸蛋白质科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/7/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 7 月 26 | 年 | 27 | 日~2025 | 年 | 7 | 月 | 日 | | 预计回购金额 | 1,000万元~2,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 40.4337万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.5762% | | | ...

Meeting Overview - The shareholders' meeting of Suzhou Nearshore Protein Technology Co., Ltd. was held on May 29, 2025, at Donghengsheng International Hotel, Suzhou [1] - A total of 56 ordinary shareholders attended the meeting, holding 47,772,421 voting rights, which accounts for 68.47% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with the following voting results: - Proposal 1: 99.8649% approval from ordinary shareholders, with 47,707,900 votes in favor [1] - Proposal 2: 99.8670% approval from ordinary shareholders, with 47,708,900 votes in favor [2] - Proposal 3: 99.8208% approval from ordinary shareholders, with 47,686,815 votes in favor [2] - Proposal 4: 99.8187% approval from ordinary shareholders, with 47,685,815 votes in favor [2] - Proposal 5: 99.8191% approval from ordinary shareholders, with 47,686,015 votes in favor [2] Legal Compliance - The meeting was convened and conducted in accordance with relevant laws, regulations, and the company's articles of association, as confirmed by the attending lawyers [3]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-021 苏州近岸蛋白质科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 29 日 （二） 股东大会召开的地点：苏州市吴江区文苑路 88 号东恒盛国际大酒店五楼 姑苏厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 56 | | --- | --- | | 普通股股东人数 | 56 | | 2、出席会议的股东所持有的表决权数量 | 47,772,421 | | 普通股股东所持有表决权数量 | 47,772,421 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.4702 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.4702 | （ ...